Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation

References

• Ortega JJ, Madero L, Martin G, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA group. J Clin Oncol. 2005;23(30):7632–7640.
   PubMed Web of Science ®Google Scholar
• Gregory J, Feusner J. Acute promyelocytic leukemia in childhood. Curr Oncol Rep. 2009;11(6):439–445.
   PubMed Web of Science ®Google Scholar
• Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106(2):447–453.
   PubMed Web of Science ®Google Scholar
• Testi AM, D'Angiò M, Locatelli F, et al. Acute promyelocytic leukemia (APL): comparison between children and adults. Mediterr J Hematol Infect Dis. 2014;6(1):e2014032.
   PubMedGoogle Scholar
• Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018;132(4):405–412.
   PubMed Web of Science ®Google Scholar
• George B, Mathews V, Poonkuzhali B, et al. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia. 2004;18(10):1587–1590.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Dworzak MN, Bochennek K, et al. First experience of the AML-Berlin-Frankfurt-Munster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoic acid. Pediatr Blood Cancer. 2017;64(8):e26461.
   Web of Science ®Google Scholar
• Strocchio L, Gurnari C, Santoro N, et al. Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukemia. Br J Haematol. 2019;185(2):360–363.
   PubMed Web of Science ®Google Scholar
• Kutny MA, Geyer S, Laumann KM, et al. Outcome of pediatric acute promyelocytic leukemia patients at Children’s Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (alliance). Pediatr Blood Cancer. 2019;66(3):e27542.
   PubMed Web of Science ®Google Scholar
• Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology. 2006;2006(1):162–168.
   Google Scholar
• Testi AM, Al-Hadad SA, Al-Jadiry MF, et al. Impact of international collaboration on the prognosis of childhood acute promyelocytic leukemia in Iraq. Haematologica. 2006;91(4):509–512.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemia. French-America-British (FAB) cooperative group. Br J Haematol. 1976;33(4):451–458.
   PubMed Web of Science ®Google Scholar
• Al-Kzayer LFY, Sakashita K, Al-Jadiry MF, et al. Analysis of KRAS and NRAS gene mutations in Arab Asian children with acute leukemia: high frequency of RAS mutations in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(12):2157–2161.
   PubMed Web of Science ®Google Scholar
• Douer D, Santillana S, Ramezani L, et al. Acute promyelocytic leukemia in patients origiginating in Latin America is associated with an increased frequency of the bcr1 subtype of the PMLRARalpha fusion gene. Br J Haematol. 2003;122(4):563–570.
   PubMed Web of Science ®Google Scholar
• Boza WB, Cruz GJ, Saenz MP, et al. High incidence of acute promyelocytic leukemia in the Caucasian population: the Costa Rica experienc. Am J Hematol. 2004;76(1):96–97.
   PubMed Web of Science ®Google Scholar
• Rizzari C, Biondi A. Tailoring treatment strategy for acute promyelocytic leukemia in low-income countries. Pediatr Blood Cancer. 2009;53(3):303–305.
   PubMed Web of Science ®Google Scholar
• Park KM, Yoo KH, Kim SK, et al. Clinical characteristics and treatment outcomes of childhood acute promyelocytic leukemia in Korea: a nationwide multicenter retrospective study by Korean Pediatric Oncology Study group. Cancer Res Treat. 2022;54(1):269–276.
   PubMed Web of Science ®Google Scholar
• Abla O, Ribeiro RC, Testi AM, et al. Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. Ann Hematol. 2017;96(9):1449–1456.
   PubMed Web of Science ®Google Scholar
• Adès L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group. Blood. 2010;115(9):1690–1696.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroupprotocol. Blood. 2002;100(13):4298–4302.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Lo Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716–4725.
   PubMed Web of Science ®Google Scholar
• Ribeiro RC, Antillon F, Pedrosa F, et al. Global pediatric oncology: lessons from partnerships between high-income countries and low- to mid-income countries. J Clin Oncol. 2016;34(1):53–61.
   PubMed Web of Science ®Google Scholar
• Howard SC, Davidson A, Luna-Fineman S, et al. A framework to develop adapted regimens to manage pediatric cancer in low- and Middle-income countries. The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). Pediatr Blood Cancer. 2017;64(Suppl 5):e26879.
   Google Scholar